A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Dry age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 23 Jan 2025 New trial record